Pall T. Onundarson: This JACC Review is Highly Biased in Favor of DOAC Drugs
Pall T. Onundarson, Professor Emeritus at Landspitali University Hospital, shared a post on LinkedIn:
“Bruno, is careful in how he chooses his words but this JACC review is highly biased in favor of DOAC drugs, just look at the whole page list of disclosures. All the studies quoted compare DOAC drugs to conventional old PT-INR monitoring of warfarin that we know today is a suboptimal monitoring method that leads to suboptimal outcomes with warfarin.
Why does the paper not mention that there are major improvements in warfarin and VKA treatment and monitoring (self-monitoring and dosing, Fiix monitoring) that could benefit patients and payers massively? To whose benefit is it to silence that such improvements exist and deserve better study? What do patients and regulators think of not being made aware of such potential benefit by medical doctors? Why are reagent and instrument manufacturers afraid of investing in such improvements if patients and payers could benefit?”
Quoting Bruno Pougault’s post:
“DOACs may not be as efficacious or as safe as the current standard of care in conditions such as mechanical heart valves, thrombotic antiphospholipid syndrome, and atrial fibrillation associated with rheumatic heart disease”
Title: When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review
Authors: Antoine Bejjani, Candrika D Khairani, Ali Assi, Gregory Piazza, Parham Sadeghipour, Azita H Talasaz, John Fanikos, Jean M Connors, Deborah M Siegal, Geoffrey D Barnes, Karlyn A Martin, Dominick J Angiolillo, Dawn Kleindorfer, Manuel Monreal, David Jimenez, Saskia Middeldorp, Mitchell S V Elkind, Christian T Ruff, Samuel Z Goldhaber, Harlan M Krumholz, Roxana Mehran, Mary Cushman, John W Eikelboom, Gregory Y H Lip, Jeffrey I Weitz, Renato D Lopes, Behnood Bikdeli
Read full paper here.
Stay informed with Hemostasis Today.
-
Jul 3, 2026, 18:08Ram Khandelwal: Why AI Is Transforming Patient Education and the Future of Healthcare
-
Jul 3, 2026, 17:55Miguel Bronchud: Why Congenital Neutropenia Is Often Missed
-
Jul 3, 2026, 17:35Patrick Rensen: Celebrating 25 Years in Endocrinology at Leiden University Medical Center
-
Jul 3, 2026, 16:54Alberico Catapano: The Role of Triglyceride Variability and the AIFA Reimbursement Gap
-
Jul 3, 2026, 16:44Barbara Lovrencic: Amplifying the Patient Voice at the EMA – Shaping the Future of ITP Care
-
Jul 3, 2026, 16:34Andrea Bisso: Exploring the T Cell Engagers in Autoimmune Diseases
-
Jul 3, 2026, 16:24Rizwan Ullah: Managing Severe Tirofiban-Induced Thrombocytopenia
-
Jul 3, 2026, 16:17Neeraj Jain: Maharashtra Strengthens Hemoglobinopathies and Thalassemia Care Through Integrated Public Health Collaboration
-
Jul 3, 2026, 16:09Tshepo Mokabane: From a VMMC Room to Hope